The Shotlee Journal
Browse Shotlee articles about Retatrutide.
Showing 9 / 60 Retatrutide articles
A new Japanese study reveals that three popular GLP-1 drugs—semaglutide, tirzepatide, and retatrutide—may offer hope for rare genetic obesity linked to MC4R deficiency. In mice models, these drugs led to significant weight loss despite faulty hunger signals. Experts discuss the potential and limitations for human treatment.
When Terra Field switched from Wegovy to Zepbound, her weight loss resumed after a plateau, silencing the 'food noise' she'd battled since childhood. Now, next-generation GLP-1 drugs like CagriSema and retatrutide promise even greater results by targeting multiple gut hormones. But as these stronger treatments advance, experts caution about the risks of losing too much weight too fast.
BPC-157 promises rapid healing for injuries and inflammation, but nearly all evidence comes from animal studies with scant human trials. As hype surges in wellness circles and amid policy shifts, experts urge caution due to safety unknowns and FDA prohibitions. This guide breaks down the science, risks, and what patients need to know.
GLP-1 medications like semaglutide and tirzepatide deliver impressive weight loss, but what happens when you stop? Pivotal trials reveal significant regain risks, underscoring obesity as a chronic condition. This guide breaks down the evidence and offers practical insights for sustained results.
Peptide therapy has surged in popularity, driven by GLP-1 drugs like Ozempic and Wegovy that transform weight management and metabolic health. This guide breaks down the science, approved uses, potential benefits, and critical risks. Gain evidence-based insights to make informed decisions.
The GLP-1 drug boom isn't just transforming bodies—it's potentially lightening airplane loads and cutting airline fuel bills. Analysts predict a slimmer society could boost profits, but what's the real story behind these medications? This guide dives into the science, data, and broader implications for your health journey.
The NHS has approved a triple-strength 7.2mg Wegovy dose, promising greater weight loss for those plateauing on standard semaglutide. One user's story highlights the frustration of switching from Mounjaro due to costs, sparking debate on higher GLP-1 doses. Discover the science, safety, and what it means for metabolic health.
Novo Nordisk and Eli Lilly dominate the GLP-1 market with powerhouse drugs like Wegovy and Zepbound. But which offers better weight loss results, tolerability, and future potential? This guide breaks down the science, clinical trials, and real-world factors to help you decide.
Demand for GLP-1 weight loss medications is soaring, but the shift to easier-to-fake oral pills spells trouble. Counterfeit versions pose serious health risks, from incorrect dosing to contamination. This guide explains the threats and equips you with strategies to stay safe.
